StemCells Inc.

StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. The company is currently conducting phase 1/2 clinical trials in chronic spinal cord injury and dry age-related macular degeneration. StemCells Inc. is also pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine. The company markets stem cell research products, including media and reagents, under the SC Proven brand.

Expert Comments:

Ching-Yi Lin, H.C. Wainwright & Co. (8/7/15)
"Yesterday, StemCells Inc. reported Q2/15 earnings in-line with expectations. . .importantly, the company offered more detail on the disparate results of its Phase 1/2 dry age-related macular degeneration (dry AMD) program. . .management has included stricter criteria in its Phase 2 Radiant trial to ensure that only patients who have measurable geographic atrophy legions are enrolled. . .we reiterate our Buy rating and price target of $1.00."

Jason Kolbert, Maxim Group (8/7/15)
"StemCells Inc. ended Q2/15 with $30M cash, which should fund operations through multiple catalysts over the next year. The company's HuCNS-SC neural stem cells have advanced to two Phase 2 studies in both dry age-related macular degeneration (dry AMD) and cervical spinal cord injury (SCI). . .data from single-dose Phase 1/2 studies was positive, we’ll see as we wait for data from the large Phase 2 studies, which could come (SCI) later in 2015."

Edward Woo, Ascendiant Capital Markets (8/7/15)
"We remain positive on StemCells Inc. Despite recent stock volatility and weakness (likely due to its recent stock raise and mixed age-related macular degeneration (AMD) study results), we believe that the company represents an interesting investment story as it is progressing generally well in its clinical trials. . .we are maintaining our Buy rating but raising our 12-month price target to $1.75 from $1.50."

Caroline Corner, Cantor Fitzgerald (8/6/15)
"On the Q2/15 earnings call, StemCells Inc. management reviewed the Phase 1/2 dry age-related macular degeneration (dry AMD) data. We are encouraged by the findings and continue to think that the company is uniquely positioned in front of two large markets, the spine and the eye. . .we think StemCells faces large opportunities in markets that have few competitive players and no approved therapies."

"I have StemCells Inc. rated Buy with a $2/share target price. . .the company is using its platform technology to address issues of the central nervous system. It has trials ongoing in spinal repair and in dry age-related macular degeneration (dry AMD) and associated geographic atrophy. Its HuCNS-SC (purified adult human neuronal cells of fetal origin) is in Phase 2 for both of those indications. Right now, the company is enrolling a Phase 2 clinical trial using its cells to repair injury to the cervical spine. It is enrolling a trial for dry AMD. . .a lot of things are going for StemCells. Safety data have been demonstrated. . .StemCells has been under pressure because of the results from its Phase 1/2 in dry AMD, which were released on June 26. The company is still analyzing those data, and it is not certain that the rate of progression of geographic atrophy was actually slowing down. . .however, patients in this trial are seeing better—seeing more contrast and reading more lines of letters. The company is moving forward with a Phase 2 geographic atrophy trial with 63 patients. . ." read more >

Jason Kolbert, Maxim Group (7/23/15)
"The U.S. District Court for the District of Maryland dismissed StemCells Inc.'s patent infringement case against Neuralstem Inc. with prejudice, in favor of Neuralstem. The case concerned certain patents surrounding StemCells's neuronal stem cells. . .we do not see this significantly impacting either company. We believe StemCells is continuing to make progress with the neuronal stem cell platform (dry-AMD and cervical spinal cord injury) and that progress should continue unimpeded by today's news. We continue to believe that with, with capital raised and multiple data-driving catalysts, 2015 is a year of inflection for StemCells."

More Expert Comments

Experts Commenting on This Company

Caroline Corner, Managing Director, Equity Research – Cantor Fitzgerald
Stephen Dunn, Senior Managing Director of Research – LifeTech Capital
Katherine Genis, Analyst – Edison Investment Research
Christopher James, Managing Director, Senior Equity Research Analyst – FBR Capital Markets
Jason Kolbert, Senior Analyst – Maxim Group
Ching-Yi Lin, Managing Director in Equity Research, Senior Biotech Analyst – H.C. Wainwright & Co.
Henry McCusker, Founder and Director of Research – Scimitar Equity
Edward Woo – Ascendiant Capital Markets

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
StemCells Inc. Content